Characterization of hepatocellular carcinoma in Mansoura university Hospitals: A case-control study of risk factors.

Ramadan, Ashraf; Ebidy, Gamal El; Elzaafarany, Maha; Galal, Ahmed; Ibrahem, Maha; Ali, Dina

doi:10.21608/mjvh.2021.211713

Cited by 3 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, bilharzia antibodies were present in 61.9% of the 21 HCC patients. Our findings concur with those of Ramadan et al (2021), who found that 67.7% of Egyptian HCC patients had schistosoma antibodies. Bilharzia was reported in this analysis as a risk factor for HCC (OR=1.625, 95% CI 0.558-4.73).…”

Section: Discussionsupporting

confidence: 93%

Detection of SMARCB1 gene mutations in Egyptian hepatocellular carcinoma patients using targeted next-generation sequencing: A pilot study

Marzok,

Elhamshary,

Shalan

et al. 2021

Research Journal of Applied Biotechnology

View full text Add to dashboard Cite

Background and objectives: Hepatocellular carcinoma (HCC) is the second most common type of cancer and has a significant mortality rate due to late identification. Although while early-stage cancer is becoming more curable, advanced forms of the disease have a poor prognosis because to a high probability of return. Understanding HCC's pathogenic process and its related genetic alterations is now crucial for effective treatment. This study aimed to detect the SMARCB1 mutations in HCC Egyptian patients using nextgeneration sequencing (NGS), and their relationships with clinicopathological traits were investigated. Methods: This cross-sectional study involved 21 HCC Egyptian participants. Using NGS panel (AmpliSeq) containing the SMARCB1 gene. Results: Among the HCC patients, the viral infections, hypertension and family history were reported as a risk factors for HCC with a significant association. As well as the clinicopathological features (ascites, portal vein invasion, metastasis and Child PUGH class) showed a significant association with HCC. The findings showed that the SMARCB1 gene had 31 single nucleotide variations (SNV), with an incidence of 86%. The alterations were distributed out in between deleterious, undefinable importance, and tolerated deviations, with missense variations (54.9%) accounting for the majority of the modifications. The clinicopathological characteristics and the SMARCB1 gene mutations did not significantly correlate. Conclusion:This study concluded that the identification of various genetic variations in the SMARCB1 gene can aid in diagnosing and prognosis of HCC.

show abstract

Section: Discussionsupporting

confidence: 93%

Detection of SMARCB1 gene mutations in Egyptian hepatocellular carcinoma patients using targeted next-generation sequencing: A pilot study

Marzok,

Elhamshary,

Shalan

et al. 2021

Research Journal of Applied Biotechnology

View full text Add to dashboard Cite

show abstract

“…In the present study, 86.8% of the HCC group was males, which is consistent with the findings of Ramadan and his colleagues, who demonstrated the predominance of HCC in males. In addition, they illustrated that variations in the level of exposure to risk factors could explain the importance of other genetic factors linked to other X-linked genetic factors and sex hormones [ 12 ].…”

Section: Discussionmentioning

confidence: 99%

“…Data analysis and fluorescence detection were conducted using 7500 ABIPRISM v.2.0.1 (Applied Biosystems, USA). The relative quantification (RQ) of the gene expression was assessed through the utilization of the comparative 2-ΔΔCT technique [ 12 ].…”

Section: Methodsmentioning

confidence: 99%

Evaluation of Circular RNA SMARCA5 as a Novel Biomarker for Hepatocellular Carcinoma

Bedair,

El-Banna,

Ahmed

et al. 2024

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is the fourth most prevalent type of cancer in Egypt and the sixth globally. Most patients with HCC are typically diagnosed during the advanced stages of the disease due to the absence of biomarkers for early detection. Consequently, these patients miss the optimal timeframe for receiving therapy. Objective: we aimed to assess the circular RNA SMARCA5 level and SMARCA5 mRNA gene expression as a potential biomarker for early detection of HCC. Methods: The present study utilized a case-control design comprising 159 participants. Participants were selected from both inpatient and outpatient hepatology and gastroenterology clinics at the National Liver Institute Hospital, Menoufia University. They were evenly distributed among three groups: Group I: 53 control subjects, Group II: 53 HCV cirrhotic patients, and Group III: 53 HCC patients. Tumor staging was done using BCLC staging system. Each patient underwent a thorough clinical examination, radiological examination, complete history taking, and serum Alpha-fetoprotein (AFP) assessment and detection of circular RNASMARCA5 and SMARCA5mRNA gene sutilizing quantitative real-time polymerase chain reaction. Results: Statistically substantial differences were observed in the examined groups in terms of AFP, SMARCA5, and CircSMARCA5 (P-value = 0.001, 0.001 & 0.001). CircSMARCA5 and SMARCA5mRNA were markedly down regulated in the HCC group compared to HCV cirrhotic patients and controls. ROC analysis for early HCC diagnosis demonstrated that the CircSMARCA5 area under the curve (AUC) at cut-off point 4.55 yielded a specificity of 83.8% and sensitivity of 91.7%. The AUC for AFP at a cut-off point of 515ng/ml yielded a specificity of 89.2% and a sensitivity of 91.3%. Conclusion: CircSMARCA5 has the potential to be a more sensitive predictor of HCC disease compared to AFP.

show abstract

Individualized HCC surveillance using risk stratification scores in advanced fibrosis and cirrhotic HCV patients who achieved SVR: Prospective study

Shiha,

Hassan,

Mousa

et al. 2024

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SummaryBackgroundSeveral HCC risk stratification scores were developed; however, none has been prospectively validated. The primary aim is to validate the clinical utility of six HCC risk scores in large prospective study of F3‐4 patients achieving SVR following DAAs according to EASL guidelines. The secondary aim is to explore whether individualized risk stratification improves detection of HCC at early stages amenable to curative treatment.MethodsThis prospective study included two cohorts: Egyptian Liver Research Institute and Hospital (ELRIAH) cohort of 463 chronic HCV patients with advanced liver disease (F3 and F4) achieved SVR with a follow‐up every 6 months according to EASL guidelines using 6 simple HCC risk scores and Tanta cohort of 492 comparable patients where individualized surveillance intervals were tailored based on HCC risk assessments using GES score as follows: low‐risk patients were followed yearly, intermediate‐risk every 6 months and high‐risk every 2–3 months.ResultsAll scores, except Watanabe post, successfully stratified patients into low‐, intermediate‐ and high‐risk groups, with log‐rank p‐value of 0.001 and Harrell's C ranging from 0.669 to 0.728. Clinical utility of these scores revealed that the highest percentage of patients classified as low risk was 42.5% using the GES, while the lowest was 8.9% using the aMAP. ELRIAH cohort, 25 patients developed HCC with 52% diagnosed at BCLC 0 and A. Tanta cohort, 35 patients developed HCC, with 80% diagnosed at BCLC 0 and A.ConclusionIndividualized risk stratification using HCC risk scores was associated with improved early‐stage detection and receipt of curative treatment.

show abstract

Characterization of hepatocellular carcinoma in Mansoura university Hospitals: A case-control study of risk factors.

Cited by 3 publications

References 36 publications

Detection of SMARCB1 gene mutations in Egyptian hepatocellular carcinoma patients using targeted next-generation sequencing: A pilot study

Detection of SMARCB1 gene mutations in Egyptian hepatocellular carcinoma patients using targeted next-generation sequencing: A pilot study

Evaluation of Circular RNA SMARCA5 as a Novel Biomarker for Hepatocellular Carcinoma

Individualized HCC surveillance using risk stratification scores in advanced fibrosis and cirrhotic HCV patients who achieved SVR: Prospective study

Contact Info

Product

Resources

About